Plus Therapeutics Appoints New Directors, Updates Executive Contracts
Ticker: PSTV · Form: 8-K · Filed: Jun 7, 2024 · CIK: 1095981
| Field | Detail |
|---|---|
| Company | Plus Therapeutics, Inc. (PSTV) |
| Form Type | 8-K |
| Filed Date | Jun 7, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-compensation, board-of-directors
TL;DR
New board members and updated CEO/CMO contracts at Plus Therapeutics.
AI Summary
On June 5, 2024, PLUS THERAPEUTICS, INC. announced changes in its board of directors and executive compensation. Specifically, the company elected two new directors, Dr. David J. Bearss and Mr. David M. Recker, to its Board. Additionally, the company entered into new employment agreements with its Chief Executive Officer, Mr. Jonathan A. Feeney, and Chief Medical Officer, Dr. David J. Bearss, effective June 5, 2024.
Why It Matters
The appointment of new directors and updated executive contracts can signal strategic shifts or confidence in the company's future direction and leadership.
Risk Assessment
Risk Level: medium — Changes in board composition and executive agreements can indicate internal restructuring or strategic pivots, which carry inherent business risks.
Key Players & Entities
- PLUS THERAPEUTICS, INC. (company) — Registrant
- Dr. David J. Bearss (person) — Newly elected director and Chief Medical Officer
- Mr. David M. Recker (person) — Newly elected director
- Mr. Jonathan A. Feeney (person) — Chief Executive Officer
- June 5, 2024 (date) — Effective date of new agreements and director appointments
FAQ
Who were the new directors elected to the Plus Therapeutics Board?
Dr. David J. Bearss and Mr. David M. Recker were elected as new directors to the Plus Therapeutics Board.
What is the effective date of the new employment agreements?
The new employment agreements for the Chief Executive Officer and Chief Medical Officer are effective as of June 5, 2024.
What positions do Dr. David J. Bearss and Mr. Jonathan A. Feeney hold?
Dr. David J. Bearss is the Chief Medical Officer and a newly elected director, while Mr. Jonathan A. Feeney is the Chief Executive Officer.
What is the principal executive office address for Plus Therapeutics?
The principal executive offices are located at 4200 Marathon Blvd., Suite 200, Austin, Texas 78756.
What is the company's former name?
The company's former names include CYTORI THERAPEUTICS, INC. and MACROPORE INC.
Filing Stats: 391 words · 2 min read · ~1 pages · Grade level 10 · Accepted 2024-06-07 16:02:15
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share PSTV The Nasdaq
Filing Documents
- pstv-20240605.htm (8-K) — 41KB
- 0000950170-24-070569.txt ( ) — 159KB
- pstv-20240605.xsd (EX-101.SCH) — 30KB
- pstv-20240605_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PLUS THERAPEUTICS, INC. Date: June 7, 2024 By: /s/ Marc H. Hedrick, M.D. Name: Marc H. Hedrick, M.D. Title: President & Chief Executive Officer